First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors
Crossref DOI link: https://doi.org/10.1007/s10637-015-0247-1
Published Online: 2015-05-08
Published Print: 2015-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ratain, Mark J.
Geary, David
Undevia, Samir D.
Coronado, Cinthya
Alfaro, Vicente
Iglesias, Jorge L.
Schilsky, Richard L.
Miguel-Lillo, Bernardo
Text and Data Mining valid from 2015-05-08
Version of Record valid from 2015-05-08
Article History
Received: 13 April 2015
Accepted: 29 April 2015
First Online: 8 May 2015